via MS Society UK
A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment.
The research is published in the January 20, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment. Additionally, more than half of the people with the secondary progressive form of MS experienced no worsening of their symptoms 10 years after a transplant.
While most people with MS are first diagnosed with relapsing-remitting MS, marked by symptom flare-ups followed by periods of remission, many people with relapsing-remitting MS eventually transition to secondary progressive MS, which does not have wide swings in symptoms but instead a slow, steady worsening of the disease.
The study involved autologous hematopoietic stem cell transplants, which use healthy blood stem cells from the participant’s own body to replace diseased cells.
“So far, conventional treatments have prevented people with MS from experiencing more attacks and worsening symptoms, but not in the long term,” said study author Matilde Inglese, M.D., Ph.D., of the University of Genoa in Italy and a member of the American Academy of Neurology. “Previous research shows more than half of the people with MS who take medication for their disease still get worse over a 10-year period. Our results are exciting because they show hematopoietic stem cell transplants may prevent someone’s MS disabilities from getting worse over the longer term.”
The study looked at 210 people with MS who received stem cell transplants from 1997 to 2019. Their average age was 35. Of those people, 122 had relapsing-remitting MS and 86 had secondary progressive MS and two had primary progressive MS.
Researchers assessed participants at six months, five years and 10 years after their transplants.
Five years into the study, researchers found that 80% of the people experienced no worsening of their MS disability. At the 10-year mark, 66% still had not experienced a worsening of disability.
When looking at just the people with the most common form of MS, researchers found 86% of them experienced no worsening of their disability five years after their transplant. Ten years later, 71% still experienced no worsening of their disability.
Also, people with progressive MS benefited from stem cell transplants. Researchers found that 71% of the people with this type of MS experienced no worsening of their disability five years after their transplants. Ten years later, 57% experienced no worsening of their disability.
“Our study demonstrates that intense immunosuppression followed by hematopoietic stem cell transplants should be considered as a treatment for people with MS, especially those who don’t respond to conventional therapy,” Inglese said.
Limitations of the study include that it was retrospective, did not include a control group and the clinicians who helped measure participants’ disability were aware that they had received stem cell transplants, so that could have led to bias. Inglese said these limitations will be addressed in future research.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Stem cell transplant
- Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide | Bone Marrow Transplantationon March 3, 2021 at 10:37 am
Higher infused total nucleated cell dose (TNC) in allogeneic bone marrow transplant (BMT) with post-transplant cyclophosphamide (PTCy) is associated with improved overall survival. As many centers ...
- Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cellson March 3, 2021 at 10:35 am
Our data offer a proof of concept for the treatment of SCD by MHC disparate non-myeloablative T cell-depleted HSCT, using anti-3rd party central memory veto CD8-positive T-cells.
- Bone marrow transplants resume at RGGGHon March 3, 2021 at 6:19 am
A 42-year-old man, who had multiple myeloma, underwent autologous hematopoietic stem cell transplantation at the hospital.
- Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplanton March 3, 2021 at 4:14 am
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological ...
- Free bone marrow transplants resume at Chennai's Rajiv Gandhi Hospital after nearly a yearon March 3, 2021 at 2:03 am
Dean Dr E Theranirajan said a bone marrow transplant is an expensive procedure and would cost several lakhs in private facilities but at RGGGH, it was being done for free ...
Go deeper with Google Headlines on:
Stem cell transplant
Go deeper with Bing News on:
- 'It is exciting': Multiple sclerosis vaccine could be byproduct of COVID-19 technologyon March 3, 2021 at 8:50 am
The breakthrough technology deployed to vaccinate against COVID-19 also has led to a promising new approach to preventing the progression of multiple sclerosis. That's an especially welcome ...
- Multiple Sclerosis Treatment Market Size Is Projected to Grow at 3.5% CAGR By 2023 | Share Analysis, Future Trends and SWOT Analysison March 3, 2021 at 12:52 am
Multiple Sclerosis Treatment Market Size, Trends and Growth Insights By Route of Administration (Injectable, Oral), Drug Type (Immunomodulators, ...
- Could rising temperatures send more people with multiple sclerosis to the hospital?on March 2, 2021 at 1:01 pm
As average temperatures around the globe climb, a preliminary study has found people with multiple sclerosis (MS) may expect worsening symptoms, enough to send them to the hospital more often. The ...
- Multiple Sclerosis Society holding virtual fundraising walkon March 2, 2021 at 6:00 am
Prevalence of MS is three times higher among women than men and an estimated 1 million Americans are living with the disease.
- The Multiple Sclerosis Association of America (MSAA) Focuses on Improving Mental Health and Wellness in Honor of MS Awareness Monthon March 1, 2021 at 9:02 am
The Multiple Sclerosis Association of America (MSAA) recognizes March as Multiple Sclerosis (MS) Awareness Month. MSAA is proud to announce the 2021 awareness campaign theme on Improving Mental Health ...